. 2022 Aug 10;5(8):e2225973. doi: 10.1001/jamanetworkopen.2022.25973

Table 2. Classification of OS Benefit Evidence of Cancer Drug Indications Approved by China’s National Medical Products Administration, 2005 to 2020.

OS benefit evidence	Indication, No. (%)^a
OS benefit evidence	All (n = 141)	Cancer drugs approved in China only (n = 30)^b	Cancer drugs also approved by FDA or EMA (n = 111)^b
Documented OS benefit	68 (48.2)	9 (30.0)	59 (53.1)
Documented lack of OS benefit	34 (24.1)	3 (10.0)	31 (27.9)
OS benefit unknown	13 (9.2)	4 (13.3)	9 (8.1)
OS benefit not evaluable	26 (18.4)	14 (46.7)	12 (10.8)

Abbreviations: EMA, European Medicine Agency; FDA, US Food and Drug Administration; OS, overall survival.

^{^a}

Percentages have been rounded and may not total 100.

^{^b}

By December 31, 2020.